VSVince Siebert

Vince Siebert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vince Siebert has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Yochai Birnbaum

    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    2 shared publications
  • Ahmad Manshad

    Division of Cardiovascular Disease, Loyola University Medical Center, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois

    1 shared publication
  • Alan John

    Department of Cardiology, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153, USA

    1 shared publication
  • Amir Darki

    Division of Cardiology, Department of Cardiology Loyola University Medical Center Maywood Illinois USA

    1 shared publication
  • Amir Darki

    Department of Interventional Cardiology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA; Cardiology, Loyola University Medical Center, Pulmonary Embolism Response Team

    1 shared publication
  • Bruce Lewis

    Division of Cardiology, Department of Cardiology Loyola University Medical Center Maywood Illinois USA

    1 shared publication

Latest Publications

  • Open Access

    A goal‐oriented hemodynamic approach to acute myocardial infarction complicated by cardiogenic shock—A single center experience

    by Vince Siebert, Jake Goldstein, Rizwan Khan, John Lopez, Amir Darki, Bruce Lewis, Lowell Steen, Demetrios Doukas

    Background: Acute myocardial infarction complicated by cardiogenic shock (AMI‐CS) is the most common cause of mortality following AMI, and treatment algorithms vary widely. We report the results of an analysis using time‐sensitive, hemodynamic goals in the treatment of AMI‐CS in a single center study.Methods: Consecutive patients with AMI‐CS from November 2016 through December 2021 were included in our retrospective analysis. Clinical characteristics and outcomes were analyzed using the electronic medical records. We identified 63 total patients who were admitted to our center with AMI‐CS, and we excluded patients who did not have clear timing of AMI onset or CS onset. We evaluated the rate of survival to hospital discharge based on the quantity of certain time‐sensitive hemodynamic goals were met.Results: We identified 63 patients who met criteria for AMI‐CS, 39 (62%) of whom survived to hospital discharge. Odds of survival were closely related to the achievement of four time‐dependent goals: cardiac power output (CPO) >0.6 Watts (W), pulmonary artery pulsatility index (PAPi) >1, lactate 1, <2 vasopressors, and lactate <4 mmol/L) at 24 h after treatment for AMI‐CS with in‐hospital mortality. Our data show, in line with previous data, that the higher number of goals met at 24 h was associated with improved in‐hospital mortality regardless of treatment strategy.


  • Open Access

    Case report of a coronary artery-right ventricular fistula following repeat endomyocardial biopsies in a heart transplant patient

    by Vincent R Siebert, Alan John, Ahmad Manshad, Amir Darki

    Background: Endomyocardial biopsy (EMB) remains the gold standard for cellular rejection surveillance in heart transplant recipients. Coronary artery fistula formation is a rare late and potentially catastrophic complication of repeated endomyocardial biopsies, without contemporary evidence on incidence or management. Case summary: A 47-year-old male was found to have a fistula between his right ventricle and his left anterior descending artery on an angiogram that was performed as a part of regular screening of coronary allograft vasculopathy. Given the low shunt fraction, asymptomatic nature, and lack of guidelines on definitive management, the patient is undergoing conservative management with regular surveillance. Discussion: Coronary artery fistulas were once thought to be rare complications of repeated EMB, but the true prevalence is likely to be higher than previously believed. Ideal treatment and monitoring is unknown given the relative rarity of the condition.


  • Meta-analysis Comparing Multivessel Versus Culprit Coronary Arterial Revascularization for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

    by Vincent R. Siebert, Sanket Borgaonkar, Xiaoming Jia, Hong Loan Nguyen, Yochai Birnbaum, Nasser M. Lakkis, Mahboob Alam


  • The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury

    by Vince Siebert, Joseph Allencherril, Yumei Ye, Xander H. T. Wehrens, Yochai Birnbaum

    MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.